Structural Modification and Biological Evaluation of 2,8-Disubstituted Adenine and Its Nucleosides as A 2A Adenosine Receptor Antagonists: Exploring the Roles of Ribose at Adenosine Receptors

Building on the preceding structural analysis and a structure-activity relationship (SAR) of 8-aryl-2-hexynyl nucleoside hA AR antagonist , we strategically inverted C2/C8 substituents and eliminated the ribose moiety. These modifications aimed to mitigate potential steric interactions between ribos...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of medicinal chemistry 2024-06, Vol.67 (12), p.10490-10507
Hauptverfasser: Kim, Gibae, Jarhad, Dnyandev B, Lee, Grim, Kim, Gyudong, Hou, Xiyan, Yu, Jinha, Lee, Chang Soo, Warnick, Eugene, Gao, Zhan-Guo, Ahn, Sang Yeop, Kwak, Dongik, Park, Kichul, Lee, Summer Dabin, Park, Tae-Uk, Jung, So-Young, Lee, Jong Hyun, Choi, Jong-Ryoul, Kim, Myeongjoong, Kim, Donghyun, Kim, Bongtae, Jacobson, Kenneth A, Jeong, Lak Shin
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Building on the preceding structural analysis and a structure-activity relationship (SAR) of 8-aryl-2-hexynyl nucleoside hA AR antagonist , we strategically inverted C2/C8 substituents and eliminated the ribose moiety. These modifications aimed to mitigate potential steric interactions between ribose and adenosine receptors. The SAR findings indicated that such inversions significantly modulated hA AR binding affinities depending on the type of ribose, whereas removal of ribose altered the functional efficacy via hA AR. Among the synthesized derivatives, 2-aryl-8-hexynyl adenine demonstrated the highest selectivity for hA AR ( = 5.0 ± 0.5 nM, / = 86) and effectively blocked cAMP production and restored IL-2 secretion in PBMCs. Favorable pharmacokinetic properties and a notable enhancement of anticancer effects in combination with an mAb immune checkpoint blockade were observed upon oral administration of . These findings establish as a viable immune-oncology therapeutic candidate.
ISSN:0022-2623
1520-4804
DOI:10.1021/acs.jmedchem.4c01003